Literature DB >> 15863147

Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.

Paul A M Meeuwissen1, Caroline Seynaeve, Cecile T M Brekelmans, Hanne J Meijers-Heijboer, Jan G M Klijn, Curt W Burger.   

Abstract

OBJECTIVE: Women at high risk of ovarian cancer are currently offered two options: either surveillance or prophylactic bilateral salpingo-oophorectomy. The efficacy and outcome of surveillance remain unclear.
METHODS: We performed a retrospective study. Between 1994 and 2000, we screened 383 high-risk women, of which 152 were BRCA1/2 mutation carriers. Surveillance consisted of annual gynecological examination, transvaginal ultrasound, and serum CA125 measurement. Exploratory or prophylactic surgery was performed in selected cases.
RESULTS: There were no screen-detected primary ovarian cancers. Abnormal results at surveillance were observed in 74 (19.3%) of women; in 47 (63.5%), the abnormalities disappeared spontaneously. Exploratory surgery was performed in 20 (27.0%) women in whom one malignancy was found (metastatic breast cancer in the ovary). A rising CA125 value prompted further (non-surgical) evaluation in three women with a history of breast cancer: recurrent breast cancer was diagnosed in two women; in the third, a chondrosarcoma was found. 133 women opted for prophylactic bilateral salpingo-oophorectomy, whereby two unexpected malignancies were found (fallopian tube cancer and metastatic breast cancer). One interval primary ovarian cancer occurred, presenting as papillary serous carcinoma of the peritoneum 14 months after prophylactic bilateral salpingo-oophorectomy. Complications of prophylactic surgery were encountered in 15 (11.5%) women.
CONCLUSIONS: Ovarian cancer surveillance has limited sensitivity, and a high number of false positive findings. This can lead to unnecessary surgical interventions, possibly resulting in surgery-related complications. It is important to inform high-risk women of these limitations. For now, prophylactic bilateral salpingo-oophorectomy remains the optimal risk-reducing strategy for women at high risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863147     DOI: 10.1016/j.ygyno.2005.01.024

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  22 in total

Review 1.  Predictors of choosing life-long screening or prophylactic surgery in women at high and moderate risk for breast and ovarian cancer.

Authors:  J R J De Leeuw; M J van Vliet; M G E M Ausems
Journal:  Fam Cancer       Date:  2008-03-14       Impact factor: 2.375

2.  Reduced Ovarian Cancer Incidence in Women Exposed to Low Dose Ionizing Background Radiation or Radiation to the Ovaries after Treatment for Breast Cancer or Rectosigmoid Cancer.

Authors:  Steven Lehrer; Sheryl Green; Kenneth E Rosenzweig
Journal:  Asian Pac J Cancer Prev       Date:  2016

3.  Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy.

Authors:  Christos Iavazzo; Ioannis D Gkegkes; Nikolaos Vrachnis
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-01-12

4.  Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.

Authors:  Susan M Domchek; Tara M Friebel; Judy E Garber; Claudine Isaacs; Ellen Matloff; Rosalind Eeles; D Gareth Evans; Wendy Rubinstein; Christian F Singer; Stephen Rubin; Henry T Lynch; Mary B Daly; Jeffrey Weitzel; Patricia A Ganz; Gabriella Pichert; Olufunmilayo I Olopade; Gail Tomlinson; Nadine Tung; Joanne L Blum; Fergus Couch; Timothy R Rebbeck
Journal:  Breast Cancer Res Treat       Date:  2010-02-24       Impact factor: 4.872

5.  Family information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutations.

Authors:  Henry T Lynch; Carrie L Snyder; Jane F Lynch; Sumedha Ghate; Steven A Narod; Gordon Gong
Journal:  Breast J       Date:  2009 Sep-Oct       Impact factor: 2.431

Review 6.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

7.  Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.

Authors:  Amy L Gross; Robert J Kurman; Russell Vang; Ie-Ming Shih; Kala Visvanathan
Journal:  J Oncol       Date:  2010-04-27       Impact factor: 4.375

Review 8.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

9.  Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?

Authors:  Dimitra Sasaroli; George Coukos; Nathalie Scholler
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

10.  The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Authors:  Patrick O Brown; Chana Palmer
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.